Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

My previous session
Most popular
Real-time Quote. Real-time Tradegate - 12/11 04:51:55 pm
78.41 EUR   +1.95%
03:17pMyoKardia Sees Topline Results from Phase 1b Study of MYK-491
11:48aSANOFI : 'Truth isn't truth' tops list of notable quotes in 2018
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

SANOFI : and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes

share with twitter share with LinkedIn share with facebook
share via e-mail
11/14/2012 | 07:15am CET

Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes

Paris, France, and Boston, Mass., - November 14, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and T1D Exchange, a non-profit organization focused on type 1 diabetes, announced today on World Diabetes Day that they will collaborate on the TEENs registry study. The aim of the study is to provide the type 1 diabetes community with a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes, and to deliver recommendations for better disease management and patients outcomes.

TEENs, also known as the "Glycemic control and quality of life in children, adolescents, and young adults with type 1 diabetes mellitus described in a worldwide, cross-sectional study in 2012," is a multinational, observational, cross-sectional study that will evaluate the percentage of type 1 diabetes patients between the ages of 8 and 25 with controlled glycemia, as measured by hemoglobin A1c (HbA1c). Secondary outcomes will include measurements of quality of life and emotional status, the relationship between glycemic control and quality of life, and the impact of factors such as medical care on these two measurements.

"To better understand how to treat young people with type 1 diabetes, we need to know how exactly they are living with the disease. Our goal with the TEENs study is to examine how clinical factors such as glycemic control impact the quality of life of this particularly vulnerable group of young people with diabetes," said Riccardo Perfetti, MD, Vice President Medical Affairs, Global Diabetes, Sanofi. "TEENs is another example of Sanofi's ongoing commitment to further develop the understanding of optimal type 1 diabetes care."

The TEENs study will enroll more than 7,000 people with type 1 diabetes in 20 countries, with a sample representative of the typical medical care in the respective country. In the US, Sanofi works in partnership with T1D Exchange for the recruitment of the young study participants and for implementation of this study. Worldwide, Sanofi partners with various clinic centers, hospitals, and healthcare professionals.

"We are excited to support Sanofi and the TEENs study with T1D Exchange's patient registry and extensive clinic network in the US. We are also honored to be designated by Sanofi as a clinical trial Center of Excellence," said Dana Ball, CEO and Cofounder of the T1D Exchange. "This collaboration demonstrates the unique efficiencies and capabilities that partnerships with foundation-driven clinical exchanges can create."

Data will be collected from healthcare professionals, parents or guardians, and patients. Anticipated outcomes include: identification of predictive factors for glucose control and acute complications of type 1 diabetes, better understanding of unmet needs of young people with type 1 diabetes in different age groups, documentation of insulin regimens in young people with type 1 diabetes, and description of the patient journey from pediatric to adult care services.
Results from the TEENs study will be presented at scientific congresses in 2013 and in 2014.


About Diabetes

Diabetes is a chronic disease that occurs as type 1 diabetes, which is an autoimmune disease characterized by the lack of insulin (the hormone that regulates blood glucose concentrations) production by the pancreas, and type 2, a metabolic disorder in which there are two main biological defects: a deficient production of insulin and reduced ability of the body to respond to the insulin
being produced. Type 1 and type 2 diabetes are characterized by an increase in blood glucose
concentrations (hyperglycemia). Over time, uncontrolled hyperglycemia leads to the macrovascular and microvascular complications of diabetes. Macrovascular complications, which affect the large blood vessels, include heart attack, stroke and peripheral vascular disease. Microvascular complications affect the small blood vessels of the eyes (retinopathy), kidney (nephropathy) and nerves (neuropathy). More than 18 million people worldwide are living with type 1 diabetes. And, the incidence of type 2 diabetes is growing at an alarming rate, with nearly 348 million people worldwide living with the condition today.

About T1D Exchange

T1D Exchange is a non-profit organization with the mission to improve outcomes of people touched by type 1 diabetes by accelerating the discovery of new approaches to research and development.
It connects the disparate stakeholders in the type 1 diabetes community by combining the critical components of traditional clinical research with the expanding fields of health information technology and social networking.
T1D Exchange evolved as a solution to mitigate barriers and inefficiencies for type 1 diabetes research and development. It is a personalized exploration platform anchored in health informatics: T1D Exchange consists of Glu, an interactive website with mobile capabilities for patients and caregivers; a network of 69 clinics across the United States; and a biorepository comprising clinically annotated patient biological samples. T1D Exchange was founded in 2011 through a grant from The Leona M. and Harry B. Helmsley Charitable Trust. More information is available at www.t1dexchange.org.

About Sanofi Diabetes

Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and
engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics,
therapies, services and devices, including innovative blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with type 1 or type 2 diabetes. Investigational compounds in the pipeline include an injectable GLP-1 receptor agonist being studied as a single agent, in combination with basal insulin, and/or in combination with oral anti- diabetic agents.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT:
SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and


statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward- looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December

31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts: Sanofi T1D Exchange

Corporate Media Relations Ellen Giller

Marisol Peron Tel: + 1 (617) 892-6132

Tel: +33 1 53 77 45 02 E-mail: egiller@t1dexchange.org

Mobile: +33 6 08 18 94 78

E-mail: mr@sanofi.com

Global Diabetes Division Communications

Tilmann Kiessling

Mobile: +49 172 61 59 291

E-mail: TilmannKiessling@sanofi.com

US Diabetes Communications

Susan Brooks

Tel: +1 (0) 9 08 98 16 56 6

Mobile: +1 (0) 2 01 57 24 99 4



distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
03:17pMyoKardia Sees Topline Results from Phase 1b Study of MYK-491
11:48aSANOFI : 'Truth isn't truth' tops list of notable quotes in 2018
12/10SANOFI : Boehringer Ingelheim plans to cut about 300 jobs in France
12/07EXCLUSIVE : Activist investor Elliott has stake in Germany's Bayer - sources
12/06Euro Health Stocks No Longer Insulated From Global Selloff -- Market Talk
12/06SANOFI : Sema4, Mount Sinai collaborate on largest Asthma study of its kind
12/06SANOFI : merges biology and tech with research deal for digital asthma lab
12/05SANOFI : to Cut Around 500 Net Jobs in France as It Moves to Restructure Globall..
More news
News from SeekingAlpha
09:16aMyoKardia down 1% premarket on early-stage MYK-491 data 
12/10BERKSHIRE HATHAWAY : Are Warren Buffett & Co. Losing Their Midas Touch? 
12/08Alnylam Pharmaceuticals Tries To Rally The Troops With A Blizzard Of New R&D .. 
12/05ALTIMMUNE : Suppressed, Immature, Or Dormant? 
12/04FDA warns on rare risks with Sanofi's MS med Lemtrada 
Financials (€)
Sales 2018 34 988 M
EBIT 2018 8 389 M
Net income 2018 5 054 M
Debt 2018 17 084 M
Yield 2018 4,01%
P/E ratio 2018 18,25
P/E ratio 2019 17,33
EV / Sales 2018 3,24x
EV / Sales 2019 3,13x
Capitalization 96 308 M
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 81,7 €
Spread / Average Target 6,2%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI7.04%109 431
JOHNSON & JOHNSON4.09%389 584
PFIZER21.26%257 520
NOVARTIS3.06%218 721
ROCHE HOLDING LTD.0.30%215 316
MERCK AND COMPANY37.59%201 321